Monoaminergic Networks of Cognitive and Behavioral Symptoms in Early Parkinson's Disease
Open Access
- 30 January 2026
- journal article
- Published by Wiley in Movement Disorders
- Vol. 41 (4) , 1004-1015
Abstract
Background: Parkinson's disease (PD) is associated with several behavioral and cognitive symptoms, the neurobiological background of which is not yet fully understood. Objectives: The aim was to investigate the association between monoamine function and four specific nonmotor symptoms in early PD using the Parkinson's Progression Markers Initiative data. Methods: [ 123 I]FP‐CIT SPECT imaging data of healthy controls ( n = 166) and patients with PD at baseline ( n = 349), 2‐year ( n = 240), and 4‐year follow‐up ( n = 140) were included. Depression, anxiety, rapid eye movement (REM) sleep behavior disorder (RBD) and cognition were evaluated using validated questionnaires. The associations between symptoms and subcortical monoamine transporter binding were analyzed voxel by voxel. Whole brain networks of symptom‐specific monoaminergic abnormalities were characterized using a functional connectome ( n = 1000) and normative neurotransmitter receptor maps. Results: Cross‐sectionally, depression was associated with reduced ventral striatum (VS) binding at 2‐ and 4‐year and dorsal raphe (DRN) at 4‐year follow‐up ( P FWE < 0.05); trait anxiety was associated with reduced DRN binding at 4‐year follow‐up ( P FWE < 0.05). Longitudinally, lower baseline binding in these regions at baseline predicted more severe future depression and anxiety ( P FWE < 0.05). RBD was most strongly linked to reduced VS binding at 2‐ and 4‐year follow‐up (nonsignificant after correction, P FWE < 0.1). Each of the symptom‐specific clusters was connected to distinct brain networks, corresponding to specific monoamine receptors: serotonin (5HT 1F , 5HT 2A , 5HT 5A ) and histamine (H 3 ) for depression; histamine (H 1 ), serotonin (5HT 1E , 5HT 1F , 5HT 2A , 5HT 3B ), and adrenergic (α 1D ) for anxiety; and adrenergic (β 2 ) and serotonin (5HT 1F , 5HT 2C , 5HT 5A ) receptors for RBD. Conclusions: The findings provide novel information about the monoaminergic networks underlying depression, anxiety, and RBD in PD. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.Keywords
Funding Information
- Turun Yliopistollinen Keskussairaala
- Turun Yliopisto
- Turun Yliopistosäätiö
This publication has 70 references indexed in Scilit:
- Depression and Nigral Neuron Density in Lewy Body Spectrum DiseasesAnnals of Neurology, 2021
- JuSpace: A tool for spatial correlation analyses of magnetic resonance imaging data with nuclear imaging derived neurotransmitter mapsHuman Brain Mapping, 2020
- Diagnosis and Treatment of Parkinson DiseaseJAMA, 2020
- Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disordersDepression and Anxiety, 2018
- Striatal dopamine in Parkinson disease: A meta‐analysis of imaging studiesAnnals of Neurology, 2017
- Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and AdolescentsJAMA Psychiatry, 2017
- Elevated serotonin transporter binding in depressed patients with Parkinson's disease: A preliminary PET study with [11C]DASBMovement Disorders, 2008
- The REM sleep behavior disorder screening questionnaire—A new diagnostic instrumentMovement Disorders, 2007
- The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot studyMovement Disorders, 2007
- N-substituted phenyltropanes as in vivo binding ligands for rapid imaging studies of the dopamine transporterSynapse, 1997